首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1881943

iPS细胞衍生血小板市场报告：趋势、预测与竞争分析（至2031年）

IPS Cell-derived Platelets Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年12月02日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

全球iPS细胞衍生血小板市场预计将成为一个充满前景的市场，这主要得益于癌症和血液疾病市场的机会，预计2025年至2031年该市场将以9.6%的复合年增长率增长。关键成长要素包括对先进血小板疗法的需求不断增长、再生医学技术的日益普及以及基于细胞的血小板生产研究的不断发展。

根据 Lucintel 的预测，在预测期内，体内再生技术有望实现更高的成长率。
从应用领域来看，血液学领域预计将呈现更高的成长率。
从区域来看，预计亚太地区在预测期内将达到最高的成长率。

iPS细胞衍生血小板市场的新趋势

由于旨在解决当前局限性和拓展临床效用的关键趋势，iPS细胞衍生血小板市场持续发展。这些趋势着重于提高生产效率、确保安全性和品质以及探索新的应用领域，预计将共同推动市场成长和普及。

自动化和可扩展生产：这一趋势利用生物反应器和机器人系统来自动化将 iPS 细胞分化为血小板的复杂过程，从而显着提高产量、降低人事费用并提高产品一致性，所有这些对于满足临床应用的大规模需求都至关重要。
同种异体现成产品：各公司正在开发具有「通用」基因设计的诱导多能干细胞株，以降低免疫排斥的风险。这一趋势正在影响市场，因为它能够提供无需患者特异性客製化的即时捐赠者产品，从而使输血更加快速方便。
基因编辑增强功能：利用 CRISPR 等基因编辑工具对 iPS 细胞进行改造，以改善血小板功能、降低免疫抗原性、提高生产效率，从而产生更有效、更安全、具有更优异治疗特性的产品，并透过将应用扩展到标准输血之外，对市场产生影响。
人工智慧的整合：人工智慧正被用于优化培养条件和预测分化结果，从而进一步简化研发流程。人工智慧的影响正在加速研发进程，缩短从实验室到临床的时间，并提高生产过程的准确性和可靠性。
聚焦冷冻保存和储存：各公司正在开发高效的iPS细胞衍生血小板冷冻保存方法，将其目前的保质期从几天延长至更长。这一趋势对物流产生了重大影响，能够实现远距的运输，并建立更可靠的供应链，这对于拓展全球市场至关重要。

这些新兴趋势正在从根本上重塑 iPSC 衍生血小板市场：向自动化、广泛的现成生产以及透过基因编辑进行增强的转变，正在将一项小众技术转变为一种可行、扩充性且全球可及的治疗选择。

iPS细胞衍生血小板市场的最新趋势

诱导多能干细胞衍生血小板市场正经历创新和策略活动的蓬勃发展。这些发展主要集中在克服传统血小板供应的挑战，例如保质期短和依赖供体，并利用先进的生物技术，为输血医学创造更可靠、更安全的替代方案。

临床试验成功：在日本完成早期人体临床试验是一个重要的里程碑。这项进展为监管部门的核准提供了必要的安全性和有效性数据，证明了iPS细胞衍生血小板的治疗潜力，并为进一步的大规模临床研究铺平了道路。
大规模生产技术的进步：采用优化生物反应器系统和分化培养基的新型生产通讯协定显着提高了产量。这些进步透过提高技术的经济可行性和扩充性，并解决商业化和推广应用的关键挑战，正在对市场产生影响。
聚焦通用供体血小板：开发出经过基因工程改造的 iPS细胞株，使其能够作为“通用供体”，这是一项重大进展，它通过减少 HLA 配型的需求、简化血小板输注的物流以及让更多患者能够更快地获得血小板输注，从而影响着市场。
策略联盟与合作：生技公司、学术机构和大型製药公司之间的合作日益增加。这些联盟整合了资源、专业知识和资金，旨在加速研究、简化产品开发流程，并透过了解复杂的监管环境和推动产品商业化进程，从而影响市场。
监管路径的发展：主要市场的监管机构正在製定针对细胞疗法技术（包括诱导多能干细胞衍生产品）的具体指导方针。此举透过提供更清晰、更可预测的市场核准路径，刺激投资并缩短产品惠及病患的时间，进而对市场产生影响。

从成功的临床试验到策略合作，这些关键进展共同推动着iPS细胞衍生血小板市场走向商业性化。它们正系统性地克服技术、经济和监管方面的障碍，并将该领域从研究阶段转变为切实可行的解决方案，以应对全球血小板短缺和输血相关挑战。

欧洲iPS细胞衍生血小板市场（按类型划分）
欧洲iPS细胞衍生血小板市场依应用领域划分
德国iPS细胞衍生血小板市场
法国iPS细胞衍生血小板市场
西班牙iPS细胞衍生血小板市场
义大利iPS细胞衍生血小板市场
英国iPS细胞衍生血小板市场

9. 亚太地区iPS细胞衍生血小板市场

亚太地区iPS细胞衍生血小板市场（按类型划分）
亚太地区iPS细胞衍生血小板市场（依应用划分）
日本iPS细胞衍生血小板市场
印度iPS细胞衍生血小板市场
中国iPS细胞衍生血小板市场
韩国iPS细胞衍生血小板市场
印尼iPS细胞衍生血小板市场

第十章世界其他地区（ROW）iPS细胞衍生血小板市场

ROW iPS细胞衍生血小板市场按类型划分
ROW iPS细胞衍生血小板市场依应用领域划分
中东iPS细胞衍生血小板市场
南美洲iPS细胞衍生血小板市场
非洲iPS细胞衍生血小板市场

第十一章竞争分析

产品系列分析
营运整合
波特五力分析
市占率分析

第十二章：机会与策略分析

价值链分析
成长机会分析
全球iPS细胞衍生血小板市场的新兴趋势
战略分析

第十三章：价值链中主要企业的概况

竞争分析
Megakaryon Corporation
Renerval Therapeutics
Xueji Shengwu
Help Therapeutics
Cynata Therapeutics
Fate Therapeutics
Century Therapeutics

第十四章附录

简介目录图表

The future of the global IPS cell-derived platelets market looks promising with opportunities in the cancer and blood disease markets. The global IPS cell-derived platelets market is expected to grow with a CAGR of 9.6% from 2025 to 2031. The major drivers for this market are the increasing demand for advanced platelet therapies, the rising adoption of regenerative medicine techniques, and the growing research in cell-based platelet production.

Lucintel forecasts that, within the type category, in vivo regeneration is expected to witness higher growth over the forecast period.
Within the application category, blood disease is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market is evolving with several key trends aimed at addressing current limitations and expanding clinical utility. These trends are centered on improving production efficiency, ensuring safety and quality, and exploring new applications, which will collectively drive the market's growth and accessibility.

Automation and Scalable Production: This trend involves the use of bioreactors and robotic systems to automate the complex process of differentiating iPSCs into platelets. The impact is a significant increase in production yield, reduced labor costs, and enhanced product consistency, which are crucial for meeting the large-scale demands of clinical applications.
Allogeneic Off-the-Shelf Products: Companies are developing iPSC lines that are genetically engineered to be "universal," reducing the risk of immune rejection. This trend is impacting the market by enabling the creation of readily available, universal-donor products that do not require patient-specific customization, thus making transfusions faster and more accessible.
Gene-Editing for Enhanced Functionality: The use of gene-editing tools like CRISPR to modify iPSCs to improve platelet function, reduce immunogenicity, or increase production efficiency is a growing trend. This is impacting the market by creating more effective and safer products with superior therapeutic properties, broadening their use beyond standard transfusions.
Integration of Artificial Intelligence: AI is being used to optimize culture conditions and predict differentiation outcomes, streamlining the development process. AI's impact is in accelerating research and development, reducing the time from lab to clinic, and improving the accuracy and reliability of manufacturing processes.
Focus on Cryopreservation and Storage: Companies are developing methods to efficiently cryopreserve IPS cell-derived platelets, extending their shelf life beyond the current few days. This trend is significantly impacting logistics, enabling long-distance transport and creating a more reliable supply chain, which is essential for global market penetration.

These emerging trends are fundamentally reshaping the IPS cell-derived platelets market. The shift towards automation, off-the-shelf products, and enhanced functionality through gene-editing is transforming a niche technology into a viable, scalable, and globally accessible therapeutic option.

Recent Developments in the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market is witnessing a surge in innovation and strategic activity. These developments are primarily focused on overcoming the challenges of traditional platelet supply, such as limited shelf life and donor dependency, by leveraging advanced biotechnologies to create a more reliable and safer alternative for transfusion medicine.

Successful Clinical Trials: The completion of initial human clinical trials in Japan has marked a significant milestone. This development has provided crucial safety and efficacy data, which is essential for regulatory approval and has demonstrated the therapeutic potential of IPS cell-derived platelets, paving the way for further large-scale clinical investigations.
Advances in Mass Production: New manufacturing protocols utilizing optimized bioreactor systems and differentiation media have led to a substantial increase in production yield. This development is impacting the market by making the technology more economically viable and scalable, addressing a key challenge to commercialization and widespread adoption.
Focus on Universal Donor Platelets: The development of iPSC lines that are genetically modified to be "universal donors" is a key development. This is impacting the market by reducing the need for HLA matching, which can simplify the logistics of platelet transfusions and make them more readily available for a broader patient population.
Strategic Partnerships and Collaborations: There has been an increase in collaborations between biotech companies, academic institutions, and pharmaceutical giants. These partnerships are impacting the market by pooling resources, expertise, and funding to accelerate research, streamline product development, and navigate the complex regulatory landscape, bringing the products closer to commercial reality.
Regulatory Pathway Development: Regulatory bodies in key markets are establishing specific guidelines for cell-based therapies, including iPSC-derived products. This development is impacting the market by providing a clearer and more predictable path to market approval, encouraging investment and reducing the time required for products to reach patients.

These key developments, from successful clinical trials to strategic collaborations, are collectively driving the IPS cell-derived platelets market toward commercial viability. They are systematically addressing the technical, economic, and regulatory hurdles, transforming the field from a research endeavor into a tangible solution for global platelet shortages and transfusion-related challenges.

Strategic Growth Opportunities in the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market presents significant strategic growth opportunities across various applications. These opportunities are driven by the unique advantages of IPS cell technology, such as scalability and reduced risk of contamination, which enable its application in areas where traditional donor-based platelets are limited.

Transfusion Medicine: An immediate opportunity lies in addressing the chronic shortage of donor platelets. The ability to produce a consistent and contamination-free supply of platelets from iPSCs is a game-changer. This offers a reliable alternative for patients requiring frequent transfusions, such as those undergoing chemotherapy or with bone marrow disorders.
Regenerative Medicine: Another key opportunity is the use of IPS cell-derived platelets in regenerative medicine applications. Platelets contain growth factors that can aid in tissue repair and wound healing. Their use in therapies for conditions like chronic wounds, orthopedic injuries, and cardiovascular diseases offers a new avenue for growth and market expansion.
Drug Discovery and Development: iPSC-derived platelets provide a valuable tool for drug screening and disease modeling. They offer a physiologically relevant human cell model for studying platelet-related disorders and testing new antiplatelet drugs. This application can accelerate the development of new therapeutics and reduce the reliance on animal testing.
Personalized Medicine: The ability to generate patient-specific platelets from their own iPSCs is a unique opportunity for personalized medicine. This can be particularly impactful for patients with alloimmune refractoriness, who do not respond to donor platelets. This niche application addresses an unmet medical need and can command premium pricing.
Gene and Cell Therapy: The market can grow by combining iPSC-derived platelets with gene and cell therapies. For example, platelets could be engineered to deliver specific therapeutic genes or molecules. This offers an innovative platform for treating genetic bleeding disorders or as a delivery vehicle for targeted drug delivery.

These strategic growth opportunities are poised to transform the IPS cell-derived platelets market. By expanding beyond traditional transfusion, the market can tap into the burgeoning fields of regenerative medicine, personalized therapy, and drug development, ensuring long-term growth and establishing IPS cell-derived platelets as a cornerstone of future medicine.

IPS Cell-derived Platelets Market Driver and Challenges

The IPS cell-derived platelets market is influenced by a complex interplay of drivers and challenges, which include various technological, economic, and regulatory factors. Understanding these dynamics is crucial for navigating the market, as they dictate the pace of innovation, investment, and ultimately, the commercial viability and patient accessibility of these products.

The factors responsible for driving the IPS cell-derived platelets market include:

1. Shortage of Donor Platelets: The limited shelf life and short supply of donor platelets, which are susceptible to bacterial contamination, is a major driver. This scarcity creates a critical need for an alternative source, which IPS cell technology can address by providing a scalable and on-demand supply.

2. Technological Advancements in Biomanufacturing: Innovations in bioreactor technology and cell culture media have improved the efficiency and yield of iPSC-derived platelet production. These advancements are making the process more cost-effective and reproducible, which is essential for moving from research to large-scale commercial manufacturing.

3. Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases like cancer and autoimmune disorders, which often require frequent platelet transfusions, is driving market growth. This demographic trend creates a growing patient population that can benefit from the reliable supply offered by IPS cell-derived platelets.

4. Reduced Risk of Transfusion-Transmitted Infections: IPS cell-derived platelets are produced in a controlled laboratory environment, significantly reducing the risk of viral and bacterial contamination. This inherent safety advantage over donor-derived platelets is a key driver for both patient and physician adoption.

5. Government Funding and Research Initiatives: Favorable government policies and public and private funding for stem cell research are accelerating the development of IPS cell therapies. This financial support helps to fund expensive research and clinical trials, which are necessary to bring products to market.

Challenges in the IPS cell-derived platelets market are:

1. High Production Costs: The current cost of manufacturing IPS cell-derived platelets is very high, primarily due to the complex processes and expensive reagents involved. This economic challenge is a major barrier to widespread commercial adoption and affordability, especially in cost-sensitive healthcare systems.

2. Regulatory Hurdles and Long Approval Times: Navigating the complex regulatory landscape for novel cell-based therapies is a significant challenge. The need for extensive clinical trials and long-term safety data, coupled with evolving regulatory guidelines, can cause significant delays in product commercialization.

3. Technical Challenges in Product Standardization: Ensuring consistency and quality of IPS cell-derived platelets from different batches is a major technical challenge. Variations in cell lines, differentiation protocols, and final product characteristics can impact efficacy and safety, requiring rigorous quality control and standardization.

The IPS cell-derived platelets market is at a critical juncture, with strong drivers pushing for innovation and significant challenges to overcome. While the demand for a safe and scalable platelet source is clear, the high costs, regulatory complexities, and technical hurdles must be systematically addressed to realize the full potential of this groundbreaking technology and make it accessible to patients worldwide.

List of IPS Cell-derived Platelets Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies IPS cell-derived platelets companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the IPS cell-derived platelets companies profiled in this report include-

Megakaryon Corporation
Renerval Therapeutics
Xueji Shengwu
Help Therapeutics
Cynata Therapeutics
Fate Therapeutics
Century Therapeutics

IPS Cell-derived Platelets Market by Segment

The study includes a forecast for the global IPS cell-derived platelets market by type, application, and region.

IPS Cell-derived Platelets Market by Type [Value from 2019 to 2031]:

In Vivo Regeneration
In Vitro Regeneration

IPS Cell-derived Platelets Market by Application [Value from 2019 to 2031]:

Cancer
Blood Disease
Others

Country Wise Outlook for the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market is experiencing significant progress, driven by the limitations of traditional donor-based platelet transfusions. This innovative field addresses challenges like short shelf life, risk of infectious diseases, and supply shortages by offering a scalable, safe, and readily available alternative for treating various bleeding disorders and for use in regenerative medicine.

United States: The U.S. market is leading in advancements due to robust funding and a strong R&D infrastructure. Major developments include clinical trials and collaborations between biotech firms and academia, focusing on scaling up production and developing "off-the-shelf" allogeneic products for applications in fields like cardiology and neurology.
China: China is a rapidly growing market for IPS cell-derived products, with increasing government support and investment in biotechnology. The focus is on building a robust R&D ecosystem and fostering partnerships to accelerate the development of cell therapies. While still in early stages, there is a strong push to catch up with global leaders.
Germany: Germany's market is characterized by a strong regulatory framework and a focus on high-quality research. Recent developments include increased investment in regenerative medicine and partnerships between public institutions and private companies. The country is leveraging its expertise in biomanufacturing to optimize production processes for IPS cell-derived products.
India: The Indian market is emerging, driven by a growing patient population with chronic diseases and rising awareness of advanced cell therapies. Recent developments include increased government funding for stem cell research and collaborations between local and international players. The country is focusing on establishing a foundation for R&D and clinical trials.
Japan: Japan is a global leader in IPS cell research and commercialization, with government backing and key collaborations. Recent milestones include the first-in-human clinical trials for IPS cell-derived platelets. Companies are focusing on mass production techniques and developing universal-type platelets to overcome the challenges of HLA compatibility and supply.

Features of the Global IPS Cell-derived Platelets Market

Market Size Estimates: Ips cell-derived platelets market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Ips cell-derived platelets market size by type, application, and region in terms of value ($B).
Regional Analysis: Ips cell-derived platelets market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the IPS cell-derived platelets market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the IPS cell-derived platelets market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the IPS cell-derived platelets market by type (in vivo regeneration and in vitro regeneration), application (cancer, blood disease, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global IPS Cell-derived Platelets Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 In Vivo Regeneration: Trends and Forecast (2019-2031)
4.4 In Vitro Regeneration: Trends and Forecast (2019-2031)

5. Global IPS Cell-derived Platelets Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Cancer: Trends and Forecast (2019-2031)
5.4 Blood Disease: Trends and Forecast (2019-2031)
5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global IPS Cell-derived Platelets Market by Region

7. North American IPS Cell-derived Platelets Market

7.1 Overview
7.2 North American IPS Cell-derived Platelets Market by Type
7.3 North American IPS Cell-derived Platelets Market by Application
7.4 United States IPS Cell-derived Platelets Market
7.5 Mexican IPS Cell-derived Platelets Market
7.6 Canadian IPS Cell-derived Platelets Market

8. European IPS Cell-derived Platelets Market

8.1 Overview
8.2 European IPS Cell-derived Platelets Market by Type
8.3 European IPS Cell-derived Platelets Market by Application
8.4 German IPS Cell-derived Platelets Market
8.5 French IPS Cell-derived Platelets Market
8.6 Spanish IPS Cell-derived Platelets Market
8.7 Italian IPS Cell-derived Platelets Market
8.8 United Kingdom IPS Cell-derived Platelets Market

9. APAC IPS Cell-derived Platelets Market

9.1 Overview
9.2 APAC IPS Cell-derived Platelets Market by Type
9.3 APAC IPS Cell-derived Platelets Market by Application
9.4 Japanese IPS Cell-derived Platelets Market
9.5 Indian IPS Cell-derived Platelets Market
9.6 Chinese IPS Cell-derived Platelets Market
9.7 South Korean IPS Cell-derived Platelets Market
9.8 Indonesian IPS Cell-derived Platelets Market

10. ROW IPS Cell-derived Platelets Market

10.1 Overview
10.2 ROW IPS Cell-derived Platelets Market by Type
10.3 ROW IPS Cell-derived Platelets Market by Application
10.4 Middle Eastern IPS Cell-derived Platelets Market
10.5 South American IPS Cell-derived Platelets Market
10.6 African IPS Cell-derived Platelets Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global IPS Cell-derived Platelets Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Megakaryon Corporation
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Renerval Therapeutics
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Xueji Shengwu
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Help Therapeutics
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Cynata Therapeutics
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.7 Fate Therapeutics
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.8 Century Therapeutics
- Company Overview
- IPS Cell-derived Platelets Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global IPS Cell-derived Platelets Market
Figure 2.1: Usage of IPS Cell-derived Platelets Market
Figure 2.2: Classification of the Global IPS Cell-derived Platelets Market
Figure 2.3: Supply Chain of the Global IPS Cell-derived Platelets Market
Figure 3.1: Driver and Challenges of the IPS Cell-derived Platelets Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global IPS Cell-derived Platelets Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global IPS Cell-derived Platelets Market ($B) by Type
Figure 4.3: Forecast for the Global IPS Cell-derived Platelets Market ($B) by Type
Figure 4.4: Trends and Forecast for In Vivo Regeneration in the Global IPS Cell-derived Platelets Market (2019-2031)
Figure 4.5: Trends and Forecast for In Vitro Regeneration in the Global IPS Cell-derived Platelets Market (2019-2031)
Figure 5.1: Global IPS Cell-derived Platelets Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global IPS Cell-derived Platelets Market ($B) by Application
Figure 5.3: Forecast for the Global IPS Cell-derived Platelets Market ($B) by Application
Figure 5.4: Trends and Forecast for Cancer in the Global IPS Cell-derived Platelets Market (2019-2031)
Figure 5.5: Trends and Forecast for Blood Disease in the Global IPS Cell-derived Platelets Market (2019-2031)
Figure 5.6: Trends and Forecast for Others in the Global IPS Cell-derived Platelets Market (2019-2031)
Figure 6.1: Trends of the Global IPS Cell-derived Platelets Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global IPS Cell-derived Platelets Market ($B) by Region (2025-2031)
Figure 7.1: North American IPS Cell-derived Platelets Market by Type in 2019, 2024, and 2031
Figure 7.2: Trends of the North American IPS Cell-derived Platelets Market ($B) by Type (2019-2024)
Figure 7.3: Forecast for the North American IPS Cell-derived Platelets Market ($B) by Type (2025-2031)
Figure 7.4: North American IPS Cell-derived Platelets Market by Application in 2019, 2024, and 2031
Figure 7.5: Trends of the North American IPS Cell-derived Platelets Market ($B) by Application (2019-2024)
Figure 7.6: Forecast for the North American IPS Cell-derived Platelets Market ($B) by Application (2025-2031)
Figure 7.7: Trends and Forecast for the United States IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 7.8: Trends and Forecast for the Mexican IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Canadian IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 8.1: European IPS Cell-derived Platelets Market by Type in 2019, 2024, and 2031
Figure 8.2: Trends of the European IPS Cell-derived Platelets Market ($B) by Type (2019-2024)
Figure 8.3: Forecast for the European IPS Cell-derived Platelets Market ($B) by Type (2025-2031)
Figure 8.4: European IPS Cell-derived Platelets Market by Application in 2019, 2024, and 2031
Figure 8.5: Trends of the European IPS Cell-derived Platelets Market ($B) by Application (2019-2024)
Figure 8.6: Forecast for the European IPS Cell-derived Platelets Market ($B) by Application (2025-2031)
Figure 8.7: Trends and Forecast for the German IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 8.8: Trends and Forecast for the French IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the Spanish IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Italian IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the United Kingdom IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 9.1: APAC IPS Cell-derived Platelets Market by Type in 2019, 2024, and 2031
Figure 9.2: Trends of the APAC IPS Cell-derived Platelets Market ($B) by Type (2019-2024)
Figure 9.3: Forecast for the APAC IPS Cell-derived Platelets Market ($B) by Type (2025-2031)
Figure 9.4: APAC IPS Cell-derived Platelets Market by Application in 2019, 2024, and 2031
Figure 9.5: Trends of the APAC IPS Cell-derived Platelets Market ($B) by Application (2019-2024)
Figure 9.6: Forecast for the APAC IPS Cell-derived Platelets Market ($B) by Application (2025-2031)
Figure 9.7: Trends and Forecast for the Japanese IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Indian IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Chinese IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the South Korean IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the Indonesian IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 10.1: ROW IPS Cell-derived Platelets Market by Type in 2019, 2024, and 2031
Figure 10.2: Trends of the ROW IPS Cell-derived Platelets Market ($B) by Type (2019-2024)
Figure 10.3: Forecast for the ROW IPS Cell-derived Platelets Market ($B) by Type (2025-2031)
Figure 10.4: ROW IPS Cell-derived Platelets Market by Application in 2019, 2024, and 2031
Figure 10.5: Trends of the ROW IPS Cell-derived Platelets Market ($B) by Application (2019-2024)
Figure 10.6: Forecast for the ROW IPS Cell-derived Platelets Market ($B) by Application (2025-2031)
Figure 10.7: Trends and Forecast for the Middle Eastern IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the South American IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the African IPS Cell-derived Platelets Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global IPS Cell-derived Platelets Market
Figure 11.2: Market Share (%) of Top Players in the Global IPS Cell-derived Platelets Market (2024)
Figure 12.1: Growth Opportunities for the Global IPS Cell-derived Platelets Market by Type
Figure 12.2: Growth Opportunities for the Global IPS Cell-derived Platelets Market by Application
Figure 12.3: Growth Opportunities for the Global IPS Cell-derived Platelets Market by Region
Figure 12.4: Emerging Trends in the Global IPS Cell-derived Platelets Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the IPS Cell-derived Platelets Market by Type and Application
Table 1.2: Attractiveness Analysis for the IPS Cell-derived Platelets Market by Region
Table 1.3: Global IPS Cell-derived Platelets Market Parameters and Attributes
Table 3.1: Trends of the Global IPS Cell-derived Platelets Market (2019-2024)
Table 3.2: Forecast for the Global IPS Cell-derived Platelets Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global IPS Cell-derived Platelets Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 4.4: Trends of In Vivo Regeneration in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 4.5: Forecast for In Vivo Regeneration in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 4.6: Trends of In Vitro Regeneration in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 4.7: Forecast for In Vitro Regeneration in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global IPS Cell-derived Platelets Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 5.4: Trends of Cancer in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 5.5: Forecast for Cancer in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 5.6: Trends of Blood Disease in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 5.7: Forecast for Blood Disease in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 5.8: Trends of Others in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 5.9: Forecast for Others in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global IPS Cell-derived Platelets Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global IPS Cell-derived Platelets Market (2025-2031)
Table 7.1: Trends of the North American IPS Cell-derived Platelets Market (2019-2024)
Table 7.2: Forecast for the North American IPS Cell-derived Platelets Market (2025-2031)
Table 7.3: Market Size and CAGR of Various Type in the North American IPS Cell-derived Platelets Market (2019-2024)
Table 7.4: Market Size and CAGR of Various Type in the North American IPS Cell-derived Platelets Market (2025-2031)
Table 7.5: Market Size and CAGR of Various Application in the North American IPS Cell-derived Platelets Market (2019-2024)
Table 7.6: Market Size and CAGR of Various Application in the North American IPS Cell-derived Platelets Market (2025-2031)
Table 7.7: Trends and Forecast for the United States IPS Cell-derived Platelets Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican IPS Cell-derived Platelets Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian IPS Cell-derived Platelets Market (2019-2031)
Table 8.1: Trends of the European IPS Cell-derived Platelets Market (2019-2024)
Table 8.2: Forecast for the European IPS Cell-derived Platelets Market (2025-2031)
Table 8.3: Market Size and CAGR of Various Type in the European IPS Cell-derived Platelets Market (2019-2024)
Table 8.4: Market Size and CAGR of Various Type in the European IPS Cell-derived Platelets Market (2025-2031)
Table 8.5: Market Size and CAGR of Various Application in the European IPS Cell-derived Platelets Market (2019-2024)
Table 8.6: Market Size and CAGR of Various Application in the European IPS Cell-derived Platelets Market (2025-2031)
Table 8.7: Trends and Forecast for the German IPS Cell-derived Platelets Market (2019-2031)
Table 8.8: Trends and Forecast for the French IPS Cell-derived Platelets Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish IPS Cell-derived Platelets Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian IPS Cell-derived Platelets Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom IPS Cell-derived Platelets Market (2019-2031)
Table 9.1: Trends of the APAC IPS Cell-derived Platelets Market (2019-2024)
Table 9.2: Forecast for the APAC IPS Cell-derived Platelets Market (2025-2031)
Table 9.3: Market Size and CAGR of Various Type in the APAC IPS Cell-derived Platelets Market (2019-2024)
Table 9.4: Market Size and CAGR of Various Type in the APAC IPS Cell-derived Platelets Market (2025-2031)
Table 9.5: Market Size and CAGR of Various Application in the APAC IPS Cell-derived Platelets Market (2019-2024)
Table 9.6: Market Size and CAGR of Various Application in the APAC IPS Cell-derived Platelets Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese IPS Cell-derived Platelets Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian IPS Cell-derived Platelets Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese IPS Cell-derived Platelets Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean IPS Cell-derived Platelets Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian IPS Cell-derived Platelets Market (2019-2031)
Table 10.1: Trends of the ROW IPS Cell-derived Platelets Market (2019-2024)
Table 10.2: Forecast for the ROW IPS Cell-derived Platelets Market (2025-2031)
Table 10.3: Market Size and CAGR of Various Type in the ROW IPS Cell-derived Platelets Market (2019-2024)
Table 10.4: Market Size and CAGR of Various Type in the ROW IPS Cell-derived Platelets Market (2025-2031)
Table 10.5: Market Size and CAGR of Various Application in the ROW IPS Cell-derived Platelets Market (2019-2024)
Table 10.6: Market Size and CAGR of Various Application in the ROW IPS Cell-derived Platelets Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern IPS Cell-derived Platelets Market (2019-2031)
Table 10.8: Trends and Forecast for the South American IPS Cell-derived Platelets Market (2019-2031)
Table 10.9: Trends and Forecast for the African IPS Cell-derived Platelets Market (2019-2031)
Table 11.1: Product Mapping of IPS Cell-derived Platelets Suppliers Based on Segments
Table 11.2: Operational Integration of IPS Cell-derived Platelets Manufacturers
Table 11.3: Rankings of Suppliers Based on IPS Cell-derived Platelets Revenue
Table 12.1: New Product Launches by Major IPS Cell-derived Platelets Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global IPS Cell-derived Platelets Market

02-2729-4219

+886-2-2729-4219

License/价格

iPS细胞衍生血小板市场报告：趋势、预测与竞争分析（至2031年）

IPS Cell-derived Platelets Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章市场概览

第三章：市场趋势与预测分析

第四章全球iPS细胞衍生血小板市场（按类型划分）

5. 全球iPS细胞衍生血小板市场（依应用划分）

第六章区域分析

第七章北美iPS细胞衍生血小板市场

8. 欧洲iPS细胞衍生血小板市场